89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft

This publication has 20 references indexed in Scilit:

• NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
  Breast Cancer Research, 2008
• NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
  Cancer Research, 2008
• Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
  Journal of Clinical Oncology, 2007
• 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
  Journal of Medicinal Chemistry, 2007
• Drugging the Cancer Chaperone HSP90
  Annals of the New York Academy of Sciences, 2007
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
  Oncogene, 2007
• Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
  Journal of Clinical Oncology, 2005
• The role of functional and molecular imaging in cancer drug discovery and development
  The British Journal of Radiology, 2003
• A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
  Nature, 2003
• Unusual expression and localization of heat‐shock proteins in human tumor cells
  International Journal of Cancer, 1992